CDK7 and neoplasm: Cdk7 levels, however, are higher in many tumor-derived human cell lines [31], and the selective Cdk7 inhibitor samuraciclib is currently evaluated in several clinical trials (NCT05963997, NCT05963984, NCT06125522).